News from bioarctic A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.
Latest
Nov 09, 2020, 02:09 ET Eisai presented latest data regarding drug candidate BAN2401 at CTAD 2020
BioArctic AB (publ) [Nasdaq Stockholm: BIOA B] announced today data on the drug candidate BAN2401 (lecanemab), which were presented by the company's...
Oct 28, 2020, 04:17 ET BioArctic's partner Eisai to present latest data on BAN2401 at CTAD conference
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company's partner Eisai will conduct four oral presentations related to the...
Oct 15, 2020, 07:24 ET BioArctic winner of the Allbright Award 2020
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has been awarded the 2020 Allbright Award for its focused work with...
Oct 06, 2020, 02:46 ET Invitation to presentation of BioArctic's Interim Report for the period January - September 2020 on October 14 at 9.30 a.m. CET
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company's Interim Report for the period January - September 2020 on Wednesday, October...
Jul 30, 2020, 04:17 ET Eisai presents the latest data from the Phase 2b open-label extension study of BAN2401 at AAIC 2020
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company's partner Eisai presented the latest data from the open-label...
Jul 22, 2020, 02:47 ET BioArctic's Partner Eisai to Present Update on the Development of BAN2401 at Alzheimer's Association International Conference 2020
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company's partner Eisai will present the study design of the Phase 3 program...
Jul 14, 2020, 02:13 ET New Global Phase 3 Program of BAN2401 Initiated in Preclinical (Asymptomatic) Alzheimer's Disease
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that its business partner Eisai, in collaboration with Alzheimer's Clinical Trials...
Jul 01, 2020, 02:43 ET Invitation to Presentation of BioArctic's Interim Report for the Period January - June 2020 on July 10 at 9.30 a.m. CET
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company's Interim Report for the period January - June 2020 on Friday, July 1, 2020, at ...
Jun 29, 2020, 02:45 ET BioArctic and University of Oslo Sign Research Agreement to Investigate Apolipoprotein E as a Drug Target for Alzheimer's Disease
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and University of Oslo, Institute of Clinical Medicine (IKM), announced today that they have signed a...
May 26, 2020, 09:48 ET Members of BioArctic's Board of Directors and Management Increase Their Shareholdings
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that seven members of the company's Board and management today have exercised options to...
May 07, 2020, 12:53 ET Report from Annual General Meeting in BioArctic (publ)
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today held its Annual General Meeting. The following resolutions were adopted. Adoption of the income...
Apr 22, 2020, 02:47 ET Interim Report for the period January - March 2020
Operations performing according to plan Key events during the first quarter 2020 As of today, BioArctic has not experienced any noteworthy...
Apr 15, 2020, 02:43 ET Invitation to Presentation of BioArctic's Interim Report for the First Quarter 2020 on April 22 at 9.30 a.m. CET
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company's Interim Report for the period January - March 2020 on Wednesday, April 22,...
Mar 03, 2020, 02:11 ET Alzheimer Patients at Swedish Clinics to be Included in Phase 3 Study of Drug Candidate BAN2401
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company's partner Eisai will include Swedish clinics in the confirmatory...
Dec 17, 2019, 10:21 ET BioArctic Announces Research Collaboration with Eisai Regarding BAN2401
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today the initiation of a research collaboration with Eisai aimed at further studying the...
Dec 05, 2019, 14:35 ET BioArctic's Partner Eisai Presents Data from the Ongoing BAN2401 Phase 2b Extension Study in Early Alzheimer's Disease
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that data from the ongoing BAN2401 Phase 2b open-label extension study in early...
Dec 02, 2019, 02:17 ET BioArctic and Eisai to Present Data on BAN2401 at the Clinical Trials on Alzheimer's Disease Conference
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that presentations related to BAN2401 will be given at the 12th Clinical Trials on...
Nov 18, 2019, 18:17 ET BioArctic Announces Results From Interim Analysis of the Phase 1/2 Study of SC0806 in Patients With Complete Spinal Cord Injury
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today the results of an interim analysis of a Phase 1/2 study of SC0806 in patients with...
Jul 18, 2019, 01:13 ET BioArctic and Eisai Present New Data Regarding BAN2401 at the Alzheimer's Association International Conference 2019
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that new data related to BAN2401 were presented on July 17. The presentations were held by...
Jul 15, 2019, 11:14 ET BioArctic's Co-Founder Received AAIC Lifetime Achievement Award
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced that on Sunday, its co-founder, Lars Lannfelt, professor in geriatrics at Uppsala University ...
Jul 11, 2019, 01:39 ET BioArctic and Eisai to Present BAN2401 at the Alzheimer's Association International Conference 2019
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that presentations related to BAN2401 will be given at the Alzheimer's Association...
May 20, 2019, 11:59 ET BioArctic Receives MEUR 15 Milestone Payment from Eisai for Start of BAN2401 Confirmatory Phase 3 Study in Early Alzheimer's Disease
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company will receive a milestone payment of MEUR 15 from its partner Eisai...
May 10, 2019, 03:51 ET BioArctic: Alzheimer's Clinical Trials Consortium and Eisai Announce BAN2401 to be Evaluated in Clinical Study for Prevention of Alzheimer's Disease
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) informed today that the Alzheimer's Clinical Trials Consortium (ACTC) and BioArctic's partner Eisai...
Apr 03, 2019, 09:56 ET BioArctic Receives Grant from Vinnova for a Collaborative Research Project to Increase Brain Uptake of Antibodies
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received a non-diluting grant of MSEK 5 from Sweden's Innovation...
Mar 21, 2019, 19:58 ET BioArctic's Partner Eisai Initiates the Confirmatory Phase 3 Study of BAN2401 in Early Alzheimer's Disease
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that its partner Eisai has initiated the global Phase 3 confirmatory study of BAN2401...
